A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity
← catalyst calendarNCT07557953 · readout in 237 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
120estimated
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-30 | actual | When the study began enrolling |
| Primary completion | 2027-04-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-13 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
Interventions
- Drug: Cagrilintide
- Drug: Placebo Cagrilintide
Primary outcome
what the primary-completion date above is the date OFRelative change in total energy intake across ad libitum breakfast, lunch, evening meal and snack box
measured From baseline (Day 2) to end of treatment (Day 127)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed